This website is intended for a UK audience

So that we can direct you to the most appropriate information about Decapeptyl SR (triptorelin), please choose one of the following options:

I am a healthcare professional in the UK*

*This section of the website is for UK healthcare professionals only and contains promotional content regarding our medicines.

Reporting of adverse events (healthcare professionals in the UK)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777

I am a patient in the UK who has been prescribed this medicine
I am a member of the general public in the UK

Reporting of side effects (patients and public in the UK)

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.

TRI-UK-004925 Date of preparation: December 2024

For UK-based Healthcare Professionals only
Search

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard

Adverse events should also be reported to the Ipsen Medical Information Department on +44(0) 1753 627777 or pharmacovigilance.uk-ie@ipsen.com

A link to the prescribing information can be found in the header.

Why Decapeptyl® SR?

Decapeptyl® SR (triptorelin) is the only luteinising hormone-releasing hormone agonist (LHRHa) for prostate cancer with a 6-monthly dosage option available in the UK.1–4

Read more

Practical prescribing

Everything you need to help prescribe LHRHa therapy with Decapeptyl® SR. Including licenced indications in prostate cancer, mechanism of action video, and dosing and administration.

Read more

Decapeptyl® SR clinical data

Review the results of the peer-reviewed, real-world, retrospective, multicentre Decapeptyl SERvice Evaluation (DESERVE)5 study and see evidence from Decapeptyl® SR clinical studies supporting the efficacy and safety of monthly, 3- monthly, and 6-monthly Decapeptyl.

Read more

Implementing Decapeptyl® SR

Download resources to help facilitate the use of less frequent LHRHa injections in your practice.

Read more

Patient support

Information for your patients who may be starting their luteinising hormone-releasing hormone agonist (LHRHa) journey with Decapeptyl® SR or who are considering changing to Decapeptyl® SR.

Patient support

References

  1. https://www.medicines.org.uk/emc/product/963 Decapeptyl® SR 3 mg Summary of Product Characteristics. Ipsen Ltd.
  2. https://www.medicines.org.uk/emc/product/780/smpc Decapeptyl® SR 11.25 mg Summary of Product Characteristics. Ipsen Ltd.
  3. https://www.medicines.org.uk/emc/product/5906/smpc Decapeptyl® SR 22.5 mg Summary of Product Characteristics. Ipsen Ltd.
  4. MIMS Online. Available from www.mims.co.uk.
  5. Cornford P, Jefferson K, Cole O, Gilbody J. Effects of initiating or switching to a six-monthly triptorelin formulation on prostate cancer patient–healthcare interactions and hospital resource use: a real-world, retrospective, non-interventional study. Oncol Ther. 2018;6:173–87.